The Food and Drug Administration (FDA) has issued a warning letter to Novo Nordisk, the manufacturer of popular weight-loss drugs Ozempic and Wegovy, for failing to report potential side effects of its GLP-1 medications, including deaths. The FDA cited five cases where patients taking the drugs experienced a stroke, considered suicide or died, one of which was caused by suicide. The company's actions suggested "systematic failures" with its surveillance, receipt, evaluation, and reporting of potential side-effects. An analysis of FDA data shows a significant spike in the company's submissions of side-effect reports in July 2025, just months after the FDA's inspection. Thousands of patients have already filed lawsuits alleging that Novo Nordic exaggerated the health risks of its drugs.